465 related articles for article (PubMed ID: 19152967)
1. A hypoallergenic variant of Der p 1 as a candidate for mite allergy vaccines.
Walgraffe D; Mattéotti C; El Bakkoury M; Garcia L; Marchand C; Bullens D; Vandenbranden M; Jacquet A
J Allergy Clin Immunol; 2009 May; 123(5):1150-6. PubMed ID: 19152967
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with the recombinant allergen ProDer p 1 complexed with the cationic lipid DiC14-amidine prevents allergic responses to house dust mite.
Jacquet A; Vanderschrick JF; Vandenbranden M; Elouahabi A; Magi M; Garcia L; Ruysschaert JM
Mol Ther; 2005 Jun; 11(6):960-8. PubMed ID: 15922967
[TBL] [Abstract][Full Text] [Related]
3. Heat denaturation affects the ProDer p 1 IgE reactivity and downregulates the development of the specific allergic response.
Magi M; Garcia L; Vandenbranden M; Palmantier R; Jacquet A
J Allergy Clin Immunol; 2004 Sep; 114(3):545-52. PubMed ID: 15356555
[TBL] [Abstract][Full Text] [Related]
4. Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy.
Asturias JA; Ibarrola I; Arilla MC; Vidal C; Ferrer A; Gamboa PM; Viñuela JE; Sanz ML; Andreu C; Martínez A
Clin Exp Allergy; 2009 Jul; 39(7):1088-98. PubMed ID: 19400901
[TBL] [Abstract][Full Text] [Related]
5. Characterization of folded recombinant Der p 5, a potential diagnostic marker allergen for house dust mite allergy.
Weghofer M; Grote M; Dall'Antonia Y; Fernández-Caldas E; Krauth MT; van Hage M; Horak F; Thomas WR; Valent P; Keller W; Valenta R; Vrtala S
Int Arch Allergy Immunol; 2008; 147(2):101-9. PubMed ID: 18520154
[TBL] [Abstract][Full Text] [Related]
6. Development of recombinant stable house dust mite allergen Der p 3 molecules for component-resolved diagnosis and specific immunotherapy.
Bouaziz A; Walgraffe D; Bouillot C; Herman J; Foguenne J; Gothot A; Louis R; Hentges F; Jacquet A; Mailleux AC; Chevigné A; Galleni M; Adam E; Dumez ME
Clin Exp Allergy; 2015 Apr; 45(4):823-34. PubMed ID: 25406386
[TBL] [Abstract][Full Text] [Related]
7. Reduction of the in vivo allergenicity of Der p 2, the major house-dust mite allergen, by genetic engineering.
Chen KW; Fuchs G; Sonneck K; Gieras A; Swoboda I; Douladiris N; Linhart B; Jankovic M; Pavkov T; Keller W; Papadopoulos NG; Valent P; Valenta R; Vrtala S
Mol Immunol; 2008 May; 45(9):2486-98. PubMed ID: 18295887
[TBL] [Abstract][Full Text] [Related]
8. Absence of immunoglobulin E synthesis and airway eosinophilia by vaccination with plasmid DNA encoding ProDer p 1.
Jacquet A; Magi M; Haumont M; Jurado M; Garcia L; Bollen A
Clin Exp Allergy; 2003 Feb; 33(2):218-25. PubMed ID: 12580915
[TBL] [Abstract][Full Text] [Related]
9. Probiotic Escherichia coli Nissle 1917 activates DC and prevents house dust mite allergy through a TLR4-dependent pathway.
Adam E; Delbrassine L; Bouillot C; Reynders V; Mailleux AC; Muraille E; Jacquet A
Eur J Immunol; 2010 Jul; 40(7):1995-2005. PubMed ID: 20432233
[TBL] [Abstract][Full Text] [Related]
10. Production and immunogenicity of hypoallergenic codon-optimized DNA vaccine encoding mature Der p 1 allergen.
Pulsawat P; Piboonpocanun S; Sirivichayakul S; Buranapraditkun S; Jacquet A; Shimada M; Okuda K; Ruxrungtham K
J Investig Allergol Clin Immunol; 2010; 20(7):582-90. PubMed ID: 21313999
[TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro immunomodulation of Der p 1 allergen-specific response by Lactobacillus plantarum bacteria.
Hisbergues M; Magi M; Rigaux P; Steuve J; Garcia L; Goudercourt D; Pot B; Pestel J; Jacquet A
Clin Exp Allergy; 2007 Sep; 37(9):1286-95. PubMed ID: 17845408
[TBL] [Abstract][Full Text] [Related]
12. Recombinant fusion proteins assembling Der p 1 and Der p 2 allergens from Dermatophagoides pteronyssinus.
Bussières L; Bordas-Le Floch V; Bulder I; Chabre H; Nony E; Lautrette A; Berrouet C; Nguefeu Y; Horiot S; Baron-Bodo V; Van Overtvelt L; De Conti AM; Schlegel A; Maguet N; Mouz N; Lemoine P; Batard T; Moingeon P
Int Arch Allergy Immunol; 2010; 153(2):141-51. PubMed ID: 20407270
[TBL] [Abstract][Full Text] [Related]
13. DNA vaccine encoding Der p 2 allergen generates immunologic protection in recombinant Der p 2 allergen-induced allergic airway inflammation mice model.
Li GP; Liu ZG; Qiu J; Ran PX; Zhong NS
Chin Med J (Engl); 2005 Apr; 118(7):534-40. PubMed ID: 15820083
[TBL] [Abstract][Full Text] [Related]
14. Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy.
Chen KW; Blatt K; Thomas WR; Swoboda I; Valent P; Valenta R; Vrtala S
J Allergy Clin Immunol; 2012 Aug; 130(2):435-43.e4. PubMed ID: 22789398
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of therapeutic sublingual vaccines in a murine model of chronic house dust mite allergic airway inflammation.
Tourdot S; Airouche S; Berjont N; Da Silveira A; Mascarell L; Jacquet A; Caplier L; Langelot M; Baron-Bodo V; Moingeon P
Clin Exp Allergy; 2011 Dec; 41(12):1784-92. PubMed ID: 22092967
[TBL] [Abstract][Full Text] [Related]
17. Engineered recombinant ovomucoid third domain can modulate allergenic response in Balb/c mice model.
Rupa P; Mine Y
Biochem Biophys Res Commun; 2006 Apr; 342(3):710-7. PubMed ID: 16494843
[TBL] [Abstract][Full Text] [Related]
18. Comparison of purified Dermatophagoides pteronyssinus allergens and extract by two-dimensional immunoblotting and quantitative immunoglobulin E inhibitions.
Weghofer M; Thomas WR; Pittner G; Horak F; Valenta R; Vrtala S
Clin Exp Allergy; 2005 Oct; 35(10):1384-91. PubMed ID: 16238800
[TBL] [Abstract][Full Text] [Related]
19. Conversion of Der p 23, a new major house dust mite allergen, into a hypoallergenic vaccine.
Banerjee S; Weber M; Blatt K; Swoboda I; Focke-Tejkl M; Valent P; Valenta R; Vrtala S
J Immunol; 2014 May; 192(10):4867-75. PubMed ID: 24733847
[TBL] [Abstract][Full Text] [Related]
20. Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination.
Ball T; Linhart B; Sonneck K; Blatt K; Herrmann H; Valent P; Stoecklinger A; Lupinek C; Thalhamer J; Fedorov AA; Almo SC; Valenta R
Allergy; 2009 Apr; 64(4):569-80. PubMed ID: 19243361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
